Exact Mass: 682.4209

Exact Mass Matches: 682.4209

Found 448 metabolites which its exact mass value is equals to given mass value 682.4209, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Cyclopassifloside II

3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl 15-[5,6-dihydroxy-5-(propan-2-yl)hexan-2-yl]-4,6-dihydroxy-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecane-7-carboxylic acid

C37H62O11 (682.4292)


Cyclopassifloside II is found in fruits. Cyclopassifloside II is a constituent of Passiflora edulis (passion fruit). Constituent of Passiflora edulis (passion fruit). Cyclopassifloside II is found in fruits.

   

PA(15:0/20:4(5Z,8Z,11Z,14Z))

[(2R)-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-3-(pentadecanoyloxy)propoxy]phosphonic acid

C38H67O8P (682.4573)


PA(15:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(15:0/20:4(8Z,11Z,14Z,17Z))

[(2R)-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-3-(pentadecanoyloxy)propoxy]phosphonic acid

C38H67O8P (682.4573)


PA(15:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:4(5Z,8Z,11Z,14Z)/15:0)

[(2R)-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-(pentadecanoyloxy)propoxy]phosphonic acid

C38H67O8P (682.4573)


PA(20:4(5Z,8Z,11Z,14Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/15:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:4(8Z,11Z,14Z,17Z)/15:0)

[(2R)-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-2-(pentadecanoyloxy)propoxy]phosphonic acid

C38H67O8P (682.4573)


PA(20:4(8Z,11Z,14Z,17Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/15:0), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0)

[(2R)-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0)

[(2R)-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:0)

[(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:0)

[(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:0)

[(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/14:1(9Z)), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/14:1(9Z))

[(2R)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/14:1(9Z)), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-[(9Z)-tetradec-9-enoyloxy]-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/14:1(9Z))

[(2R)-2-[(9Z)-tetradec-9-enoyloxy]-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:3(5Z,11Z,14Z)-O(8,9)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/14:1(9Z)), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-[(9Z)-tetradec-9-enoyloxy]-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/14:1(9Z))

[(2R)-2-[(9Z)-tetradec-9-enoyloxy]-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:3(8Z,11Z,14Z)-O(5,6)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/14:1(9Z)), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:1(9Z)), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:1(9Z))

[(2R)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:1(9Z)), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:1(9Z)), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:1(9Z)), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:1(9Z)), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:1(9Z)), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:1(9Z)), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:1(9Z))

[(2R)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:1(9Z)), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:1(9Z))

[(2R)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:1(9Z)), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(14:1(9Z)/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/14:1(9Z))

[(2R)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/14:1(9Z)), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-14:0)

[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-14:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-14:0)

[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-14:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-14:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-14:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-14:0)

[(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-14:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-14:0)

[(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-14:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(i-14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-14:0)

[(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H63O9P (682.4209)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-14:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

3-O-beta-Glucosylplatycodigenin

5,11-Dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H58O12 (682.3928)


3-O-Beta-D-Glucopyranosylplatycodigenin is an oleanane-type triterpenoid isolated from roots of Platycodon grandiflorum. 3-O-Beta-D-Glucopyranosylplatycodigenin exhibits anti-proliferative activities against HSC-T6 cell line with an IC50 of 13.36 μM[1].

   

Combreglucoside

Combreglucoside

C36H58O12 (682.3928)


   

Trachelosperoside E-1

Trachelosperoside E-1

C36H58O12 (682.3928)


   

Trachelosperoside B-1

Trachelosperoside B-1

C36H58O12 (682.3928)


   

Methyl sartortuoate

Methyl sartortuoate

C41H62O8 (682.4444)


   
   

28-O-beta-D-glucopyranosyl-6beta,23-dihydroxytormentic acid

28-O-beta-D-glucopyranosyl-6beta,23-dihydroxytormentic acid

C36H58O12 (682.3928)


   

Diepoxynyalolide

Diepoxynyalolide

C41H62O8 (682.4444)


   

Methyl tortuoate A

(+)-Methyl tortuoate A

C41H62O8 (682.4444)


   

14-Acetoxy-15-hydroxyirpexan

14-Acetoxy-15-hydroxyirpexan

C38H66O10 (682.4656)


   

Methyl tortuoate B

(+)-Methyl tortuoate B

C41H62O8 (682.4444)


   

Ximaolide A

Ximaolide A

C41H62O8 (682.4444)


   
   

Ximaolide E

Ximaolide E

C41H62O8 (682.4444)


   

Ximaolide D

Ximaolide D

C41H62O8 (682.4444)


   

Rubescensin M

Rubescensin M

C40H58O9 (682.4081)


   
   

Dehydro fucoxanthin acetate

Dehydro fucoxanthin acetate

C44H58O6 (682.4233)


   

milbemycins VM48633

milbemycins VM48633

C39H54O10 (682.3717)


   

(2alpha,3beta,12beta)-3-(beta-D-glucopyranosyloxy)-2,12,21-trihydroxy-19-oxo-18,19-secours-13(18)-en-28-oic acid|bodinioside A

(2alpha,3beta,12beta)-3-(beta-D-glucopyranosyloxy)-2,12,21-trihydroxy-19-oxo-18,19-secours-13(18)-en-28-oic acid|bodinioside A

C36H58O12 (682.3928)


   

bruceajavanone A 7-acetate

bruceajavanone A 7-acetate

C40H58O9 (682.4081)


   

MEGxp0_000950

MEGxp0_000950

C36H58O12 (682.3928)


   

camelliagenine A, 16-beta,beta-dimethylacrylate 3,22,28-triacetate

camelliagenine A, 16-beta,beta-dimethylacrylate 3,22,28-triacetate

C41H62O8 (682.4444)


   

(2beta,3beta,9beta,10alpha,16alpha,20xi,24xi)-20,24-epoxy-2-(beta-D-glucopyranosyloxy)-3,16,25,26-tetrahydroxy-9-methyl-19-norlanost-5-en-11-one

(2beta,3beta,9beta,10alpha,16alpha,20xi,24xi)-20,24-epoxy-2-(beta-D-glucopyranosyloxy)-3,16,25,26-tetrahydroxy-9-methyl-19-norlanost-5-en-11-one

C36H58O12 (682.3928)


   

3-O-|A-D-Glucopyranosylplatycodigenin

3-O-|A-D-Glucopyranosylplatycodigenin

C36H58O12 (682.3928)


   

Deacylgymnemic acid

Deacylgymnemic acid

C36H58O12 (682.3928)


   
   
   

3beta-O-beta-D-glucopyranosyl-1alpha,25,31-trihydroxycycloartan-28-oic acid|nerviside B

3beta-O-beta-D-glucopyranosyl-1alpha,25,31-trihydroxycycloartan-28-oic acid|nerviside B

C37H62O11 (682.4292)


   

6alpha,23,24,25-tetraol-16betaacetoxy-23(R),24(R)-9,19-cyclolanosta-3beta-O-xyloside|bicusposide F

6alpha,23,24,25-tetraol-16betaacetoxy-23(R),24(R)-9,19-cyclolanosta-3beta-O-xyloside|bicusposide F

C37H62O11 (682.4292)


   
   

2alpha,3beta,19alpha,23,30-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-glucopyranosyl ester

2alpha,3beta,19alpha,23,30-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-glucopyranosyl ester

C36H58O12 (682.3928)


   
   

lobophytone M

lobophytone M

C41H62O8 (682.4444)


   

2-O-beta-D-glucopyranosido-23,24-dihydrocucurbitacin F|hemsamabilinin B

2-O-beta-D-glucopyranosido-23,24-dihydrocucurbitacin F|hemsamabilinin B

C36H58O12 (682.3928)


   

Arg Arg Lys Ser His

Arg Arg Lys Ser His

C27H50N14O7 (682.3987)


   

17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one

NCGC00169462-02!17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one

C36H58O12 (682.3928)


   

C36H58O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi,18xi,19alpha)-2,3,19,23,24-pentahydroxy-28-oxoolean-12-en-28-yl]

NCGC00347771-02_C36H58O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,9xi,18xi,19alpha)-2,3,19,23,24-pentahydroxy-28-oxoolean-12-en-28-yl]-

C36H58O12 (682.3928)


   

C36H58O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,6beta,9xi,18xi,19alpha)-2,3,6,19,23-pentahydroxy-28-oxoolean-12-en-28-yl]

NCGC00169662-02_C36H58O12_beta-D-Glucopyranose, 1-O-[(2alpha,3beta,5xi,6beta,9xi,18xi,19alpha)-2,3,6,19,23-pentahydroxy-28-oxoolean-12-en-28-yl]-

C36H58O12 (682.3928)


   

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,8R,9R,10R,11R,12aR)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,8R,9R,10R,11R,12aR)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,10R,11R,12aR)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,10R,11R,12aR)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one [IIN-based: Match]

NCGC00169462-02!17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one [IIN-based: Match]

C36H58O12 (682.3928)


   

17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one [IIN-based on: CCMSLIB00000847134]

NCGC00169462-02!17-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one [IIN-based on: CCMSLIB00000847134]

C36H58O12 (682.3928)


   

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,8R,9R,10R,11R,12aR)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate_major

[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aS,6bR,8R,9R,10R,11R,12aR)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate_major

C36H58O12 (682.3928)


   

RRKSH

Arg Arg Lys Ser His

C27H50N14O7 (682.3987)


   
   

PA(13:0/22:4(7Z,10Z,13Z,16Z))

1-tridecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(15:0/20:4(5Z,8Z,11Z,14Z))

1-pentadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(15:1(9Z)/20:3(8Z,11Z,14Z))

1-(9Z-pentadecenoyl)-2-(8Z,11Z,14Z-eicosatrienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(17:0/18:4(6Z,9Z,12Z,15Z))

1-heptadecanoyl-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(17:1(9Z)/18:3(6Z,9Z,12Z))

1-(9Z-heptadecenoyl)-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(17:1(9Z)/18:3(9Z,12Z,15Z))

1-(9Z-heptadecenoyl)-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(17:2(9Z,12Z)/18:2(9Z,12Z))

1-(9Z,12Z-heptadecadienoyl)-2-(9Z,12Z-octadecadienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(18:2(9Z,12Z)/17:2(9Z,12Z))

1-(9Z,12Z-octadecadienoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(18:3(6Z,9Z,12Z)/17:1(9Z))

1-(6Z,9Z,12Z-octadecatrienoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(18:3(9Z,12Z,15Z)/17:1(9Z))

1-(9Z,12Z,15Z-octadecatrienoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(18:4(6Z,9Z,12Z,15Z)/17:0)

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-heptadecanoyl-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(20:3(8Z,11Z,14Z)/15:1(9Z))

1-(8Z,11Z,14Z-eicosatrienoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(20:4(5Z,8Z,11Z,14Z)/15:0)

1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-pentadecanoyl-glycero-3-phosphate

C38H67O8P (682.4573)


   

PA(22:4(7Z,10Z,13Z,16Z)/13:0)

1-(7Z,10Z,13Z,16Z-docosatetraenoyl)-2-tridecanoyl-glycero-3-phosphate

C38H67O8P (682.4573)


   

Cyclopassifloside II

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 15-[5,6-dihydroxy-5-(propan-2-yl)hexan-2-yl]-4,6-dihydroxy-7,12,16-trimethylpentacyclo[9.7.0.0^{1,3}.0^{3,8}.0^{12,16}]octadecane-7-carboxylate

C37H62O11 (682.4292)


   

(4R,9?)-2,16,20,25-Tetrahydroxy-9,10,14-trimethyl-11,22-dioxo-4,9-cyclo-9,10-secocholest-5-en-1-yl ?-D-glucopyranoside

(4R,9?)-2,16,20,25-Tetrahydroxy-9,10,14-trimethyl-11,22-dioxo-4,9-cyclo-9,10-secocholest-5-en-1-yl ?-D-glucopyranoside

C36H58O12 (682.3928)


   

PA 35:4

1-(9Z,12Z-octadecadienoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C38H67O8P (682.4573)


   
   

9-Octadecenoic acid(9Z)-, tin(2+) salt (2:1)

9-Octadecenoic acid(9Z)-, tin(2+) salt (2:1)

C36H66O4Sn (682.3983)


   

calcium,bis(2-ethylhexyl) phosphate

calcium,bis(2-ethylhexyl) phosphate

C32H68CaO8P2 (682.4015)


   

2,3,16,20,25-Pentahydroxycucurbita-5-ene-11,22-dio

2,3,16,20,25-Pentahydroxycucurbita-5-ene-11,22-dio

C36H58O12 (682.3928)


   

mycinamicin III(1+)

mycinamicin III(1+)

C36H60NO11+ (682.4166)


   

H-Abu-Abu-Abu-Abu-Abu-Abu-Abu-Abu-al

H-Abu-Abu-Abu-Abu-Abu-Abu-Abu-Abu-al

C32H58N8O8 (682.4377)


   

PA(14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C37H63O9P (682.4209)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0)

C37H63O9P (682.4209)


   

PA(i-14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(i-14:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C37H63O9P (682.4209)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-14:0)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-14:0)

C37H63O9P (682.4209)


   

PA(i-14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(i-14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-14:0)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-14:0)

C37H63O9P (682.4209)


   

PA(14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(14:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0)

C37H63O9P (682.4209)


   

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0)

C37H63O9P (682.4209)


   

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:0)

C37H63O9P (682.4209)


   

PA(14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:0)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:0)

C37H63O9P (682.4209)


   

PA(14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C37H63O9P (682.4209)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:0)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:0)

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(14:1(9Z)/20:3(5Z,8Z,11Z)-O(14R,15S))

C37H63O9P (682.4209)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/14:1(9Z))

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(14:1(9Z)/20:3(5Z,8Z,14Z)-O(11S,12R))

C37H63O9P (682.4209)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/14:1(9Z))

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:3(5Z,11Z,14Z)-O(8,9))

PA(14:1(9Z)/20:3(5Z,11Z,14Z)-O(8,9))

C37H63O9P (682.4209)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/14:1(9Z))

PA(20:3(5Z,11Z,14Z)-O(8,9)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-O(5,6))

PA(14:1(9Z)/20:3(8Z,11Z,14Z)-O(5,6))

C37H63O9P (682.4209)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/14:1(9Z))

PA(20:3(8Z,11Z,14Z)-O(5,6)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(20))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(14:1(9Z)/20:4(6E,8Z,11Z,14Z)-OH(5S))

C37H63O9P (682.4209)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:1(9Z))

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(17))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(14:1(9Z)/20:4(5Z,8Z,11Z,13E)-OH(15S))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:1(9Z))

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(14:1(9Z)/20:4(5Z,8Z,10E,14Z)-OH(12S))

C37H63O9P (682.4209)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:1(9Z))

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(14:1(9Z)/20:4(5E,8Z,12Z,14Z)-OH(11R))

C37H63O9P (682.4209)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:1(9Z))

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(14:1(9Z)/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(14:1(9Z)/20:4(5Z,7E,11Z,14Z)-OH(9))

C37H63O9P (682.4209)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/14:1(9Z))

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/14:1(9Z))

C37H63O9P (682.4209)


   

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-14:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-14:0)

C37H63O9P (682.4209)


   

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(i-14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-14:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-14:0)

C37H63O9P (682.4209)


   

PA(i-14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(i-14:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C37H63O9P (682.4209)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-14:0)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-14:0)

C37H63O9P (682.4209)


   

PA(i-14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(i-14:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C37H63O9P (682.4209)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-14:0)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-14:0)

C37H63O9P (682.4209)


   

(5R,6S,7S)-5,6-dihydroxy-8-(alpha-D-galactosyloxy)-7-octanamido-N-(8-phenyloctyl)octanamide

(5R,6S,7S)-5,6-dihydroxy-8-(alpha-D-galactosyloxy)-7-octanamido-N-(8-phenyloctyl)octanamide

C36H62N2O10 (682.4404)


   

NAGlySer 18:5/17:2

NAGlySer 18:5/17:2

C40H62N2O7 (682.4557)


   

NAGlySer 22:6/13:1

NAGlySer 22:6/13:1

C40H62N2O7 (682.4557)


   

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-tetracos-13-enoate

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-tetracos-13-enoate

C33H63O12P (682.4057)


   

Dgdg O-9:0_9:0

Dgdg O-9:0_9:0

C33H62O14 (682.4139)


   

Smgdg O-9:0_15:1

Smgdg O-9:0_15:1

C33H62O12S (682.3962)


   

Smgdg O-22:1_2:0

Smgdg O-22:1_2:0

C33H62O12S (682.3962)


   

Smgdg O-20:1_4:0

Smgdg O-20:1_4:0

C33H62O12S (682.3962)


   

Smgdg O-17:1_7:0

Smgdg O-17:1_7:0

C33H62O12S (682.3962)


   

Smgdg O-16:1_8:0

Smgdg O-16:1_8:0

C33H62O12S (682.3962)


   

Smgdg O-19:1_5:0

Smgdg O-19:1_5:0

C33H62O12S (682.3962)


   

Smgdg O-8:0_16:1

Smgdg O-8:0_16:1

C33H62O12S (682.3962)


   

Smgdg O-21:1_3:0

Smgdg O-21:1_3:0

C33H62O12S (682.3962)


   

Smgdg O-15:1_9:0

Smgdg O-15:1_9:0

C33H62O12S (682.3962)


   

Smgdg O-18:1_6:0

Smgdg O-18:1_6:0

C33H62O12S (682.3962)


   

Dgdg O-16:0_2:0

Dgdg O-16:0_2:0

C33H62O14 (682.4139)


   

Dgdg O-11:0_7:0

Dgdg O-11:0_7:0

C33H62O14 (682.4139)


   

Dgdg O-13:0_5:0

Dgdg O-13:0_5:0

C33H62O14 (682.4139)


   

Dgdg O-12:0_6:0

Dgdg O-12:0_6:0

C33H62O14 (682.4139)


   

Dgdg O-10:0_8:0

Dgdg O-10:0_8:0

C33H62O14 (682.4139)


   

Dgdg O-8:0_10:0

Dgdg O-8:0_10:0

C33H62O14 (682.4139)


   

Dgdg O-15:0_3:0

Dgdg O-15:0_3:0

C33H62O14 (682.4139)


   

Dgdg O-14:0_4:0

Dgdg O-14:0_4:0

C33H62O14 (682.4139)


   

Smgdg O-11:0_13:1

Smgdg O-11:0_13:1

C33H62O12S (682.3962)


   

Smgdg O-10:0_14:1

Smgdg O-10:0_14:1

C33H62O12S (682.3962)


   

Smgdg O-14:1_10:0

Smgdg O-14:1_10:0

C33H62O12S (682.3962)


   

Smgdg O-13:1_11:0

Smgdg O-13:1_11:0

C33H62O12S (682.3962)


   

PE-Cer 15:3;2O/20:2;O

PE-Cer 15:3;2O/20:2;O

C37H67N2O7P (682.4686)


   

PE-Cer 17:3;2O/18:2;O

PE-Cer 17:3;2O/18:2;O

C37H67N2O7P (682.4686)


   

PE-Cer 19:3;2O/16:2;O

PE-Cer 19:3;2O/16:2;O

C37H67N2O7P (682.4686)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C37H63O9P (682.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (Z)-tridec-9-enoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (Z)-tridec-9-enoate

C37H63O9P (682.4209)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] undecanoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] undecanoate

C33H63O12P (682.4057)


   

[1-decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate

[1-decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate

C33H63O12P (682.4057)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] decanoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] decanoate

C33H63O12P (682.4057)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] (Z)-tridec-9-enoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] (Z)-tridec-9-enoate

C33H63O12P (682.4057)


   
   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C36H59O10P (682.3846)


   

PEtOH 15:1_18:3

PEtOH 15:1_18:3

C38H67O8P (682.4573)


   

PEtOH 16:2_17:2

PEtOH 16:2_17:2

C38H67O8P (682.4573)


   

PMeOH 16:1_18:3

PMeOH 16:1_18:3

C38H67O8P (682.4573)


   

PEtOH 13:0_20:4

PEtOH 13:0_20:4

C38H67O8P (682.4573)


   

PMeOH 18:1_16:3

PMeOH 18:1_16:3

C38H67O8P (682.4573)


   

PMeOH 16:0_18:4

PMeOH 16:0_18:4

C38H67O8P (682.4573)


   

PMeOH 18:0_16:4

PMeOH 18:0_16:4

C38H67O8P (682.4573)


   

PMeOH 14:0_20:4

PMeOH 14:0_20:4

C38H67O8P (682.4573)


   

PEtOH 17:0_16:4

PEtOH 17:0_16:4

C38H67O8P (682.4573)


   

PMeOH 17:2_17:2

PMeOH 17:2_17:2

C38H67O8P (682.4573)


   

PMeOH 16:2_18:2

PMeOH 16:2_18:2

C38H67O8P (682.4573)


   

PEtOH 15:0_18:4

PEtOH 15:0_18:4

C38H67O8P (682.4573)


   

PEtOH 17:1_16:3

PEtOH 17:1_16:3

C38H67O8P (682.4573)


   

PMeOH 12:0_22:4

PMeOH 12:0_22:4

C38H67O8P (682.4573)


   

PMeOH 14:1_20:3

PMeOH 14:1_20:3

C38H67O8P (682.4573)


   

PEtOH 13:1_20:3

PEtOH 13:1_20:3

C38H67O8P (682.4573)


   

[1-Octanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

[1-Octanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

C32H58O15 (682.3776)


   

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C38H66O10 (682.4656)


   

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C38H66O10 (682.4656)


   

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

C32H58O15 (682.3776)


   

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tetradecanoate

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tetradecanoate

C32H58O15 (682.3776)


   

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentadecanoate

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentadecanoate

C32H58O15 (682.3776)


   

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

C32H58O15 (682.3776)


   

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

C32H58O15 (682.3776)


   

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

C32H58O15 (682.3776)


   

[6-[2,3-Di(dodecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[6-[2,3-Di(dodecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H66O10 (682.4656)


   

[1-[(Z)-tridec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[(Z)-tridec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C38H66O10 (682.4656)


   

[1-tridecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-tridecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C38H66O10 (682.4656)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C36H59O10P (682.3846)


   

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C38H67O8P (682.4573)


   

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

(1-heptadecanoyloxy-3-phosphonooxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C38H67O8P (682.4573)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C38H67O8P (682.4573)


   

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C38H67O8P (682.4573)


   

[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C38H67O8P (682.4573)


   

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C38H67O8P (682.4573)


   

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C38H67O8P (682.4573)


   

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C38H67O8P (682.4573)


   

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H67O8P (682.4573)


   

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (Z)-nonadec-9-enoate

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (Z)-nonadec-9-enoate

C38H67O8P (682.4573)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C38H67O8P (682.4573)


   

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

C38H67O8P (682.4573)


   

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H66O10 (682.4656)


   

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H67O8P (682.4573)


   

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,12E)-octadeca-9,12-dienoate

C38H67O8P (682.4573)


   

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H67O8P (682.4573)


   

[1-[(E)-tridec-8-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[(E)-tridec-8-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C38H66O10 (682.4656)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C38H67O8P (682.4573)


   

[1-carboxy-3-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

[1-carboxy-3-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

C41H64NO7+ (682.4683)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C38H67O8P (682.4573)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C38H67O8P (682.4573)


   

[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C41H64NO7+ (682.4683)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C38H67O8P (682.4573)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] nonadecanoate

C38H67O8P (682.4573)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (7E,9E)-nonadeca-7,9-dienoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (7E,9E)-nonadeca-7,9-dienoate

C38H67O8P (682.4573)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9E,11E)-octadeca-9,11-dienoate

C38H67O8P (682.4573)


   

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H67O8P (682.4573)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C36H59O10P (682.3846)


   

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-tridecanoyloxy-3-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-tridecanoyloxy-3-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (6E,9E)-octadeca-6,9-dienoate

C38H67O8P (682.4573)


   

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H66O10 (682.4656)


   

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (E)-nonadec-9-enoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (E)-nonadec-9-enoate

C38H67O8P (682.4573)


   

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (2E,4E)-octadeca-2,4-dienoate

C38H67O8P (682.4573)


   

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H66O10 (682.4656)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C38H67O8P (682.4573)


   

[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C41H64NO7+ (682.4683)


   

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-2-heptadecanoyloxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H67O8P (682.4573)


   

[1-tridecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-tridecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C38H66O10 (682.4656)


   

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H66O10 (682.4656)


   

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-[(E)-heptadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H67O8P (682.4573)


   

[(2S,3S,6S)-6-[(2S)-2,3-di(dodecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-2,3-di(dodecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C38H67O8P (682.4573)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C36H59O10P (682.3846)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C38H67O8P (682.4573)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C36H59O10P (682.3846)


   

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-1-heptadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C38H67O8P (682.4573)


   

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-tridecanoyloxy-2-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-tridecanoyloxy-2-undecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C38H67O8P (682.4573)


   

[1-carboxy-3-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

[1-carboxy-3-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

C41H64NO7+ (682.4683)


   

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-1-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C38H67O8P (682.4573)


   

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C33H62O12S (682.3962)


   

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C38H67O8P (682.4573)


   

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C38H67O8P (682.4573)


   

2-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-undecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-undecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

2-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-nonanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-nonanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

2-[[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C37H65NO8P+ (682.4448)


   

MGDG 11:0_18:3

MGDG 11:0_18:3

C38H66O10 (682.4656)


   
   

MGDG O-29:4;O

MGDG O-29:4;O

C38H66O10 (682.4656)


   
   
   
   
   
   
   
   

PA 14:0/20:5;O

PA 14:0/20:5;O

C37H63O9P (682.4209)


   

PA 14:1/20:4;O

PA 14:1/20:4;O

C37H63O9P (682.4209)


   

PA 20:2/13:4;O2

PA 20:2/13:4;O2

C36H59O10P (682.3846)


   

PA 20:3/13:3;O2

PA 20:3/13:3;O2

C36H59O10P (682.3846)


   

PA 22:2/12:3;O

PA 22:2/12:3;O

C37H63O9P (682.4209)


   
   
   
   
   
   
   
   
   
   

PG O-20:0/7:2;O3

PG O-20:0/7:2;O3

C33H63O12P (682.4057)


   

PG O-20:0/8:1;O2

PG O-20:0/8:1;O2

C34H67O11P (682.4421)


   
   
   
   
   
   
   
   
   
   
   
   
   

PI P-14:0/10:0 or PI O-14:1/10:0

PI P-14:0/10:0 or PI O-14:1/10:0

C33H63O12P (682.4057)


   
   

PI P-20:0/4:0 or PI O-20:1/4:0

PI P-20:0/4:0 or PI O-20:1/4:0

C33H63O12P (682.4057)


   
   

PI P-22:0/2:0 or PI O-22:1/2:0

PI P-22:0/2:0 or PI O-22:1/2:0

C33H63O12P (682.4057)


   
   

PI P-24:0 or PI O-24:1

PI P-24:0 or PI O-24:1

C33H63O12P (682.4057)


   
   
   
   
   

2-[(8s,11s,14r)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[(8s,11s,14r)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

methyl (1r,2s,7s,10s,14r,17s,20s,21s,22e,26s,27s,30r)-2-hydroxy-17-isopropyl-1,5,10,14,23,27-hexamethyl-8,15,18-trioxo-31,32-dioxapentacyclo[24.4.1.1²⁷,³⁰.0⁴,²¹.0⁷,²⁰]dotriaconta-4,22-diene-20-carboxylate

methyl (1r,2s,7s,10s,14r,17s,20s,21s,22e,26s,27s,30r)-2-hydroxy-17-isopropyl-1,5,10,14,23,27-hexamethyl-8,15,18-trioxo-31,32-dioxapentacyclo[24.4.1.1²⁷,³⁰.0⁴,²¹.0⁷,²⁰]dotriaconta-4,22-diene-20-carboxylate

C41H62O8 (682.4444)


   

(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

16-({7-hydroxy-6,9a-dimethyl-1-methylidene-2h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h,11ah-phenanthro[1,2-b]furan-6-yl}methoxy)-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-7,9,10,15,18-pentol

16-({7-hydroxy-6,9a-dimethyl-1-methylidene-2h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h,11ah-phenanthro[1,2-b]furan-6-yl}methoxy)-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-7,9,10,15,18-pentol

C40H58O9 (682.4081)


   

(6e,10r,11s,14r,15r,18e)-10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

(6e,10r,11s,14r,15r,18e)-10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

C38H66O10 (682.4656)


   

1-[5-(1,2-dihydroxypropan-2-yl)-2-methyloxolan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

1-[5-(1,2-dihydroxypropan-2-yl)-2-methyloxolan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

methyl (1s,5r,8r,12s,15r,18r,19r,20e,25r,28s,29r)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

methyl (1s,5r,8r,12s,15r,18r,19r,20e,25r,28s,29r)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

C41H62O8 (682.4444)


   

methyl (1s,2s,4s,8r,11r,15s,18r,21s,22r,23z,27r)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

methyl (1s,2s,4s,8r,11r,15s,18r,21s,22r,23z,27r)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

C41H62O8 (682.4444)


   

methyl 19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl 19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

(5r)-5-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-8,16-dihydroxy-5,9,14-trimethyl-11-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

(5r)-5-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-8,16-dihydroxy-5,9,14-trimethyl-11-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

C44H58O6 (682.4233)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

3-o-β-d-glucopyranosyl platycodigenin

NA

C36H58O12 (682.3928)


{"Ingredient_id": "HBIN009225","Ingredient_name": "3-o-\u03b2-d-glucopyranosyl platycodigenin","Alias": "NA","Ingredient_formula": "C36H58O12","Ingredient_Smile": "CC1(CCC2(C(C1)C3=CCC4C(C3(CC2O)C)(CCC5C4(CC(C(C5(CO)CO)OC6C(C(C(C(O6)CO)O)O)O)O)C)C)C(=O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15631","TCMID_id": "8710","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

beesioside p

NA

C37H62O11 (682.4292)


{"Ingredient_id": "HBIN017692","Ingredient_name": "beesioside p","Alias": "NA","Ingredient_formula": "C37H62O11","Ingredient_Smile": "CC(=O)OC1C(C(C2(C1(C3CCC4C(C(CCC45C3(C5)CC2)OC6C(C(C(CO6)O)O)O)(C)C)C)C)C(C)(CCC(C(C)(C)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2209","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

methyl 4,27-dihydroxy-18-isopropyl-6,11,15,24,28-pentamethyl-2-methylidene-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl 4,27-dihydroxy-18-isopropyl-6,11,15,24,28-pentamethyl-2-methylidene-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

9,12-dihydroxy-2-(2-hydroxy-3-methyl-4-oxopentyl)-4a,4b,7,7,10a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6,6a,8,9,10,10b,11,12-decahydro-3h-chrysene-2-carboxylic acid

9,12-dihydroxy-2-(2-hydroxy-3-methyl-4-oxopentyl)-4a,4b,7,7,10a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6,6a,8,9,10,10b,11,12-decahydro-3h-chrysene-2-carboxylic acid

C36H58O12 (682.3928)


   

2-[(8s,11s,14r)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[(8s,11s,14r)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

2-[3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

8,14,18,21-tetrahydroxy-19-(1-hydroxyethyl)-3,16-diisopropyl-4-methyl-13-(2-methylpropyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacosa-17,20-diene-2,5,12,15-tetrone

8,14,18,21-tetrahydroxy-19-(1-hydroxyethyl)-3,16-diisopropyl-4-methyl-13-(2-methylpropyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacosa-17,20-diene-2,5,12,15-tetrone

C31H54N8O9 (682.4014)


   

methyl (1s,5r,8r,12s,15r,18s,19r,20e,25r,28s,29r)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

methyl (1s,5r,8r,12s,15r,18s,19r,20e,25r,28s,29r)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

C41H62O8 (682.4444)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8r,8ar,9s,10r,11r,12ar,12br,14bs)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8r,8ar,9s,10r,11r,12ar,12br,14bs)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

methyl (1r,2s,5r,8s,12r,15r,19r,21r,23r,26r,28r,31z)-19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl (1r,2s,5r,8s,12r,15r,19r,21r,23r,26r,28r,31z)-19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

methyl (1r,2s,4s,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2s,4s,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

(4as,6as,6br,8r,8ar,10s,12as,12br,13s,14bs)-8,13-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8r,8ar,10s,12as,12br,13s,14bs)-8,13-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H58O12 (682.3928)


   

5-(4,8-dimethylnona-3,7-dien-1-yl)-8,16-dihydroxy-5,9,14-trimethyl-11-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

5-(4,8-dimethylnona-3,7-dien-1-yl)-8,16-dihydroxy-5,9,14-trimethyl-11-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

C44H58O6 (682.4233)


   

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

C41H62O8 (682.4444)


   

methyl 20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl 20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

(2r,3s,4s,5r,6r)-6-{[(1s,2s,3ar,5ar,5br,7ar,9s,11ar,11br,13ar,13bs)-2-hydroxy-3a-(hydroxymethyl)-1-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a-pentamethyl-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol

(2r,3s,4s,5r,6r)-6-{[(1s,2s,3ar,5ar,5br,7ar,9s,11ar,11br,13ar,13bs)-2-hydroxy-3a-(hydroxymethyl)-1-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a-pentamethyl-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol

C38H66O10 (682.4656)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,3s,4s,6s,7s,8r,11s,12s,15r,16r)-15-[(2r,5s)-5,6-dihydroxy-5-isopropylhexan-2-yl]-4,6-dihydroxy-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecane-7-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,3s,4s,6s,7s,8r,11s,12s,15r,16r)-15-[(2r,5s)-5,6-dihydroxy-5-isopropylhexan-2-yl]-4,6-dihydroxy-7,12,16-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecane-7-carboxylate

C37H62O11 (682.4292)


   

2-[(2s,8s,11s,14r,17s)-17-[(2r)-butan-2-yl]-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[(2s,8s,11s,14r,17s)-17-[(2r)-butan-2-yl]-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-14-isopropyl-11-(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

(1r,2r,3as,3bs,7r,8s,9ar,9br,11ar)-1-[(2s,5r)-5-[(2s)-1,2-dihydroxypropan-2-yl]-2-methyloxolan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3bs,7r,8s,9ar,9br,11ar)-1-[(2s,5r)-5-[(2s)-1,2-dihydroxypropan-2-yl]-2-methyloxolan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

methyl (1s,2s,4r,8r,11r,15s,18r,21r,22r,23z,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1s,2s,4r,8r,11r,15s,18r,21r,22r,23z,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8r,8ar,9r,10r,11r,12ar,12br,14bs)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8r,8ar,9r,10r,11r,12ar,12br,14bs)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3bs,7s,8s,9ar,9br,11ar)-1-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

(3r,11s,17r,22as)-11-benzyl-9-hydroxy-3-[(4r)-4-methoxypentyl]-6,13,16-trimethyl-17-(2-methylpropyl)-3h,4h,5h,8h,11h,14h,17h,20h,21h,22h,22ah-pyrrolo[2,1-c]1-oxa-4,7,10,13-tetraazacycloicosane-1,12,15,18-tetrone

(3r,11s,17r,22as)-11-benzyl-9-hydroxy-3-[(4r)-4-methoxypentyl]-6,13,16-trimethyl-17-(2-methylpropyl)-3h,4h,5h,8h,11h,14h,17h,20h,21h,22h,22ah-pyrrolo[2,1-c]1-oxa-4,7,10,13-tetraazacycloicosane-1,12,15,18-tetrone

C38H58N4O7 (682.4305)


   

methyl (1r,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-4,27-dihydroxy-18-isopropyl-6,11,15,24,28-pentamethyl-2-methylidene-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,4r,8s,11s,15r,18s,21s,22s,23e,27r,28s)-4,27-dihydroxy-18-isopropyl-6,11,15,24,28-pentamethyl-2-methylidene-9,16,19-trioxo-31-oxatetracyclo[26.2.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

methyl (1s,5r,8s,11r,15s,18s,19r,20e,24s,26s,29r,30s)-30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

methyl (1s,5r,8s,11r,15s,18s,19r,20e,24s,26s,29r,30s)-30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

C41H62O8 (682.4444)


   

15-benzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-3,6,12-tris(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

15-benzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-3,6,12-tris(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C37H58N6O6 (682.4418)


   

(5r)-5-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-8,16-dihydroxy-5,9,14-trimethyl-11-[(6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

(5r)-5-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-8,16-dihydroxy-5,9,14-trimethyl-11-[(6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1,3,7,9,13-pentaene-12,15-dione

C44H58O6 (682.4233)


   

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

methyl 2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl 2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

(1r,2s,5s,7r,8r,9s,10s,11r,15s,16s,18r)-16-{[(3ar,5as,6s,7r,9as,9bs,11as)-7-hydroxy-6,9a-dimethyl-1-methylidene-2h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h,11ah-phenanthro[1,2-b]furan-6-yl]methoxy}-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-7,9,10,15,18-pentol

(1r,2s,5s,7r,8r,9s,10s,11r,15s,16s,18r)-16-{[(3ar,5as,6s,7r,9as,9bs,11as)-7-hydroxy-6,9a-dimethyl-1-methylidene-2h,3ah,5h,5ah,7h,8h,9h,9bh,10h,11h,11ah-phenanthro[1,2-b]furan-6-yl]methoxy}-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-7,9,10,15,18-pentol

C40H58O9 (682.4081)


   

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,21',24'-trihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 3-methylbut-2-enoate

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,21',24'-trihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 3-methylbut-2-enoate

C39H54O10 (682.3717)


   

methyl 30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

methyl 30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

C41H62O8 (682.4444)


   

methyl 2-hydroxy-17-isopropyl-1,5,10,14,23,27-hexamethyl-8,15,18-trioxo-31,32-dioxapentacyclo[24.4.1.1²⁷,³⁰.0⁴,²¹.0⁷,²⁰]dotriaconta-4,22-diene-20-carboxylate

methyl 2-hydroxy-17-isopropyl-1,5,10,14,23,27-hexamethyl-8,15,18-trioxo-31,32-dioxapentacyclo[24.4.1.1²⁷,³⁰.0⁴,²¹.0⁷,²⁰]dotriaconta-4,22-diene-20-carboxylate

C41H62O8 (682.4444)


   

methyl (1r,5s,8s,12r,15s,18s,19s,20e,25s,28r,29s)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

methyl (1r,5s,8s,12r,15s,18s,19s,20e,25s,28r,29s)-29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

C41H62O8 (682.4444)


   

2-[(2s,8s,11s,14r,17s)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[(2s,8s,11s,14r,17s)-3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

methyl (1r,2z,5r,6s,9r,10s,13e,15s,16s,19s,22r,26s,27e,29s)-5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

methyl (1r,2z,5r,6s,9r,10s,13e,15s,16s,19s,22r,26s,27e,29s)-5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

C41H62O8 (682.4444)


   

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H58O12 (682.3928)


   

4-(acetyloxy)-1-[2-(acetyloxy)-5-(3,3-dimethyloxiran-2-yl)oxolan-3-yl]-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl hexanoate

4-(acetyloxy)-1-[2-(acetyloxy)-5-(3,3-dimethyloxiran-2-yl)oxolan-3-yl]-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl hexanoate

C40H58O9 (682.4081)


   

methyl (1s,2r,4z,8r,11r,15s,18s,21r,22s,23z,27s,28s)-2,28-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-4,6,23-triene-21-carboxylate

methyl (1s,2r,4z,8r,11r,15s,18s,21r,22s,23z,27s,28s)-2,28-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-4,6,23-triene-21-carboxylate

C41H62O8 (682.4444)


   

(2r,6r)-6-[(1r,3as,3br,4r,5as,7r,9as,9bs,11s,11ar)-4-{[(2r,3r,4s,5r,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-7,11-dihydroxy-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methylheptyl acetate

(2r,6r)-6-[(1r,3as,3br,4r,5as,7r,9as,9bs,11s,11ar)-4-{[(2r,3r,4s,5r,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-7,11-dihydroxy-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methylheptyl acetate

C37H62O11 (682.4292)


   

6-(but-2-en-2-yl)-3,21',24'-trihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 3-methylbut-2-enoate

6-(but-2-en-2-yl)-3,21',24'-trihydroxy-5,11',13'-trimethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl 3-methylbut-2-enoate

C39H54O10 (682.3717)


   

methyl (1s,2z,5s,6r,9r,10r,13e,15r,16s,19r,22s,26r,27z,29r)-5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

methyl (1s,2z,5s,6r,9r,10r,13e,15r,16s,19r,22s,26r,27z,29r)-5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

C41H62O8 (682.4444)


   

methyl (1s,2s,5s,8r,12s,15s,20s,21s,23r,26s,28r,31e)-20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl (1s,2s,5s,8r,12s,15s,20s,21s,23r,26s,28r,31e)-20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

methyl 5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

methyl 5,10-dihydroxy-19-isopropyl-1,5,9,13,22,26-hexamethyl-18,21-dioxo-31,32-dioxapentacyclo[26.2.1.1⁶,⁹.0²,¹⁵.0¹⁶,²⁹]dotriaconta-2,13,27-triene-16-carboxylate

C41H62O8 (682.4444)


   

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

1-(2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl)-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one

C36H58O12 (682.3928)


   

8,13-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

8,13-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H58O12 (682.3928)


   

(2s)-5-carbamimidamido-2-{[(2e,4s)-1-hydroxy-4-[(2s,3r)-2-{[(2s)-1-hydroxy-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butylidene]amino}-n,3-dimethylpentanamido]-2,5-dimethylhex-2-en-1-ylidene]amino}pentanoic acid

(2s)-5-carbamimidamido-2-{[(2e,4s)-1-hydroxy-4-[(2s,3r)-2-{[(2s)-1-hydroxy-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butylidene]amino}-n,3-dimethylpentanamido]-2,5-dimethylhex-2-en-1-ylidene]amino}pentanoic acid

C36H58N8O5 (682.453)


   

6-{[2-hydroxy-3a-(hydroxymethyl)-1-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a-pentamethyl-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol

6-{[2-hydroxy-3a-(hydroxymethyl)-1-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a-pentamethyl-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol

C38H66O10 (682.4656)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8ar,10r,11r,12ar,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4ar,6as,6br,8ar,10r,11r,12ar,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

(6e,18e)-10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

(6e,18e)-10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

C38H66O10 (682.4656)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8ar,10r,11r,12ar,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8ar,10r,11r,12ar,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

(2s,3s)-2-[(2s)-2-{[(2s)-2-[(2s,3s)-n,3-dimethyl-2-[(2s)-n-methyl-2-[(2e)-n-methyl-3-(methylsulfanyl)prop-2-enamido]propanamido]pentanamido]-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido]-n,3-dimethylpentanimidic acid

(2s,3s)-2-[(2s)-2-{[(2s)-2-[(2s,3s)-n,3-dimethyl-2-[(2s)-n-methyl-2-[(2e)-n-methyl-3-(methylsulfanyl)prop-2-enamido]propanamido]pentanamido]-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido]-n,3-dimethylpentanimidic acid

C34H62N6O6S (682.4451)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8r,8ar,9r,10r,11r,12ar,12br,14br)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8r,8ar,9r,10r,11r,12ar,12br,14br)-1,8,10,11-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8ar,10r,11r,12as,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,4as,6as,6br,8ar,10r,11r,12as,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

10,15-dihydroxy-2,6,10,15,19,23-hexamethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,6,18,22-tetraen-11-yl acetate

C38H66O10 (682.4656)


   

(1s,3br,4r,5ar,9as,9br,10r,11as)-4-(acetyloxy)-1-[(2r,3s,5s)-2-(acetyloxy)-5-[(2s)-3,3-dimethyloxiran-2-yl]oxolan-3-yl]-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl hexanoate

(1s,3br,4r,5ar,9as,9br,10r,11as)-4-(acetyloxy)-1-[(2r,3s,5s)-2-(acetyloxy)-5-[(2s)-3,3-dimethyloxiran-2-yl]oxolan-3-yl]-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl hexanoate

C40H58O9 (682.4081)


   

methyl (1s,2s,5s,8r,12s,15s,20s,21s,23r,26r,28r,31z)-20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl (1s,2s,5s,8r,12s,15s,20s,21s,23r,26r,28r,31z)-20-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

2-(2-{[2-(n,3-dimethyl-2-{n-methyl-2-[n-methyl-3-(methylsulfanyl)prop-2-enamido]propanamido}pentanamido)-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido)-n,3-dimethylpentanimidic acid

2-(2-{[2-(n,3-dimethyl-2-{n-methyl-2-[n-methyl-3-(methylsulfanyl)prop-2-enamido]propanamido}pentanamido)-1-hydroxy-3-methylbutylidene]amino}-n,3-dimethylbutanamido)-n,3-dimethylpentanimidic acid

C34H62N6O6S (682.4451)


   

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

methyl (1r,2s,4r,8s,11s,15r,18s,21s,22s,23e,27s)-2,4-dihydroxy-18-isopropyl-2,6,11,15,24-pentamethyl-28-methylidene-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23-diene-21-carboxylate

C41H62O8 (682.4444)


   

methyl 29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

methyl 29-hydroxy-15-isopropyl-3,8,12,21,25,29-hexamethyl-6,13,16,24-tetraoxo-31-oxatetracyclo[26.2.1.0²,¹⁹.0⁵,¹⁸]hentriaconta-2,20-diene-18-carboxylate

C41H62O8 (682.4444)


   

2-[3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[3,6,9,12,15,18-hexahydroxy-8-(1h-indol-3-ylmethyl)-17-isopropyl-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C34H50N8O7 (682.3802)


   

(3s,6r,8r,13s,16r,19s,22r)-8,14,18,21-tetrahydroxy-19-[(1r)-1-hydroxyethyl]-3,16-diisopropyl-4-methyl-13-(2-methylpropyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacosa-17,20-diene-2,5,12,15-tetrone

(3s,6r,8r,13s,16r,19s,22r)-8,14,18,21-tetrahydroxy-19-[(1r)-1-hydroxyethyl]-3,16-diisopropyl-4-methyl-13-(2-methylpropyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacosa-17,20-diene-2,5,12,15-tetrone

C31H54N8O9 (682.4014)


   

methyl 2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

methyl 2,4-dihydroxy-18-isopropyl-2,6,11,15,24,28-hexamethyl-9,16,19-trioxo-31-oxatetracyclo[25.3.1.0⁵,²².0⁸,²¹]hentriaconta-5,23,28-triene-21-carboxylate

C41H62O8 (682.4444)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H58O12 (682.3928)


   

(2r,4as,4br,6ar,8r,9r,10ar,10br,12r)-9,12-dihydroxy-2-[(2r,3r)-2-hydroxy-3-methyl-4-oxopentyl]-4a,4b,7,7,10a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6,6a,8,9,10,10b,11,12-decahydro-3h-chrysene-2-carboxylic acid

(2r,4as,4br,6ar,8r,9r,10ar,10br,12r)-9,12-dihydroxy-2-[(2r,3r)-2-hydroxy-3-methyl-4-oxopentyl]-4a,4b,7,7,10a-pentamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6,6a,8,9,10,10b,11,12-decahydro-3h-chrysene-2-carboxylic acid

C36H58O12 (682.3928)


   

5-carbamimidamido-2-{[1-hydroxy-4-(2-{[1-hydroxy-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butylidene]amino}-n,3-dimethylpentanamido)-2,5-dimethylhex-2-en-1-ylidene]amino}pentanoic acid

5-carbamimidamido-2-{[1-hydroxy-4-(2-{[1-hydroxy-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butylidene]amino}-n,3-dimethylpentanamido)-2,5-dimethylhex-2-en-1-ylidene]amino}pentanoic acid

C36H58N8O5 (682.453)


   

3,4,5-trihydroxy-6-{[8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}oxane-2-carboxylic acid

3,4,5-trihydroxy-6-{[8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}oxane-2-carboxylic acid

C36H58O12 (682.3928)


   

methyl (1r,2r,5r,8s,12r,15r,19r,21r,23r,26r,28r,31e)-19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

methyl (1r,2r,5r,8s,12r,15r,19r,21r,23r,26r,28r,31e)-19-hydroxy-5-isopropyl-8,12,17,21,26,31-hexamethyl-4,7,14-trioxo-22,27-dioxapentacyclo[16.14.0.0²,¹⁵.0²¹,²³.0²⁶,²⁸]dotriaconta-17,31-diene-2-carboxylate

C41H62O8 (682.4444)


   

(3s,6r,9s,12s,15r,20as)-15-benzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-3,6,12-tris(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(3s,6r,9s,12s,15r,20as)-15-benzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-3,6,12-tris(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C37H58N6O6 (682.4418)


   

methyl (1s,5r,8s,11r,15s,18s,19r,20e,24s,26r,29r,30s)-30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

methyl (1s,5r,8s,11r,15s,18s,19r,20e,24s,26r,29r,30s)-30-hydroxy-8-isopropyl-3,11,15,21,26,30-hexamethyl-7,10,17-trioxo-25,32-dioxapentacyclo[27.2.1.0²,¹⁹.0⁵,¹⁸.0²⁴,²⁶]dotriaconta-2,20-diene-5-carboxylate

C41H62O8 (682.4444)